Genmark Diagnostics, Inc. (GNMK): Jon Faiz Kayyem , SVP, Research & Development of Genmark Diagnostics, Inc. sold 135 shares on May 2, 2016. The Insider selling transaction was reported by the company on May 4, 2016 to the Securities and Exchange Commission. The shares were sold at $5.79 per share for a total value of $781.65 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 4, 2016, Ingo Chakravarty (SVP, International) sold 396 shares at $5.79 per share price.On May 4, 2016, Hany Massarany (President and CEO) sold 1,160 shares at $5.79 per share price.Also, On May 4, 2016, Eric Stier (SVP & General Counsel) sold 363 shares at $5.79 per share price.On Mar 14, 2016, Michael Kagnoff (director) purchased 2,500 shares at $4.90 per share price.
Shares of GenMark Diagnostics Inc (GNMK) ended Wednesday, May 4, 2016 session in red amid volatile trading. The shares closed down -0.07 points or -1.23% at $5.63 with 2,83,977 shares getting traded. Post opening the session at $5.5, the shares hit an intraday low of $5.46 and an intraday high of $5.79 and the price vacillated in this range throughout the day. The company has a market cap of $241 M and the number of outstanding shares has been calculated to be 4,27,57,475 shares. The 52-week high of GenMark Diagnostics Inc is $10.84 and the 52-week low is $4.2.
Company has been under the radar of several Street Analysts.GenMark Diagnostics Inc is Reiterated by Needham to Buy while Lowering the Price Target of the company shares to $ 11 from a previous price target of $13 . The Rating was issued on Feb 24, 2016.
GenMark Diagnostics Inc. (GenMark) is a molecular diagnostics company. The Company is focused on developing and commercializing its eSensor detection technology. The Company’s electrochemical technology enables detection of multiple distinct biomarkers in a single sample. The Company’s XT-8 system received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular research and diagnostic tests with a workstation and disposable test cartridges. Its XT-8 system supports up to 24 independent test cartridges each of which can be run independently resulting in a workflow for its focused customers which are primarily hospitals and reference laboratories. It has an installed base of approximately 540 XT-8 analyzers or placements with its customers.